Improving lipophilicity of 5-(1-acetyl-5-phenylpyrazolidin-3-ylidene)-1,3-dimethylbarbituric acid increases its efficacy to activate hypoxia-inducible factors

Bioorg Med Chem. 2022 Nov 1:73:117039. doi: 10.1016/j.bmc.2022.117039. Epub 2022 Sep 29.

Abstract

Hypoxia-inducible factor (HIF) activators aid the treatment of renal anemia and ischemia. Recently, PyrzA (5-(1-acetyl-5-phenylpyrazolidin-3-ylidene)-1,3-dimethylbarbituric acid), a HIF activator by PHD inhibition without a 2-oxoglutarate moiety was reported. However, PyrzA has low lipophilicity, and it was necessary to improve its solubility by synthesizing derivatives. In this study, we synthesized and evaluated a higher lipophilic derivative of PyrzA and found that it exhibited higher HIF activity and stabilizing ability at low concentrations compared to Roxadustat, a commercially available HIF activator.

Keywords: 2-oxoglutarate; Hypoxia-inducible factor; Hypoxic stress; PHD inhibitors; Pyrazolidine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Barbiturates
  • Humans
  • Hypoxia*
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Hypoxia-Inducible Factor-Proline Dioxygenases
  • Ketoglutaric Acids*

Substances

  • 1,3-dimethylbarbituric acid
  • Barbiturates
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Hypoxia-Inducible Factor-Proline Dioxygenases
  • Ketoglutaric Acids
  • PyrzA compound